D-1065-2016 Class II Terminated

Recalled by Allergan Sales, LLC — Waco, TX

FDA drug recall D-1065-2016 was initiated by Allergan Sales, LLC on May 10, 2016 and is designated Class II. Reason for recall: Failed Content Uniformity Specifications. The recall status is terminated (terminated Dec 6, 2017).

Recall details

Product Type
Drugs
Report Date
Jul 13, 2016
Initiation Date
May 10, 2016
Termination Date
Dec 6, 2017
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Tazorac (tazarotene) Gel 0.05%, 15 x 3.5g, sample packs, Allergan Inc, Irvine, CA 92612. UPC 300238335159

Reason for recall

Failed Content Uniformity Specifications.

Distribution pattern

Nationwide and Puerto Rico

Code information

Lot #: 84126, Exp FEB/2017

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1065-2016
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1065-2016. Report a data issue: hello@regdatalab.com.